Published in Clin Infect Dis on October 01, 2003
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother (2007) 3.54
Aspergillus infections in transplant recipients. Clin Microbiol Rev (2005) 2.82
Efflux-mediated antifungal drug resistance. Clin Microbiol Rev (2009) 2.44
Assessment of ribosomal large-subunit D1-D2, internal transcribed spacer 1, and internal transcribed spacer 2 regions as targets for molecular identification of medically important Aspergillus species. J Clin Microbiol (2005) 1.86
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell (2008) 1.73
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother (2004) 1.46
Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob Agents Chemother (2004) 1.36
Coding tandem repeats generate diversity in Aspergillus fumigatus genes. Eukaryot Cell (2007) 1.23
Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother (2005) 1.23
Conidiation color mutants of Aspergillus fumigatus are highly pathogenic to the heterologous insect host Galleria mellonella. PLoS One (2009) 1.14
Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. J Antimicrob Chemother (2010) 1.09
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. Antimicrob Agents Chemother (2004) 1.08
Detection of Aspergillus fumigatus and a mutation that confers reduced susceptibility to itraconazole and posaconazole by real-time PCR and pyrosequencing. J Clin Microbiol (2005) 1.02
Fatal invasive infection with fungemia due to Microascus cirrosus after heart and lung transplantation in a patient with cystic fibrosis. J Clin Microbiol (2011) 0.99
Immunosuppression related to collagen-vascular disease or its treatment. Proc Am Thorac Soc (2005) 0.95
Management of invasive aspergillosis in patients with COPD: rational use of voriconazole. Int J Chron Obstruct Pulmon Dis (2009) 0.91
Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature. Eur J Med Res (2011) 0.90
Will resistance in fungi emerge on a scale similar to that seen in bacteria? Eur J Clin Microbiol Infect Dis (2008) 0.88
PrtT-regulated proteins secreted by Aspergillus fumigatus activate MAPK signaling in exposed A549 lung cells leading to necrotic cell death. PLoS One (2011) 0.88
Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother (2005) 0.81
Crystal structures of the fungal pathogen Aspergillus fumigatus protein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug design. Protein Sci (2014) 0.78
Therapy of murine pulmonary aspergillosis with antibody-alliinase conjugates and alliin. Antimicrob Agents Chemother (2009) 0.77
Invasive aspergillosis in a renal transplant recipient successfully treated with interferon-gamma. Case Rep Transplant (2012) 0.76
Lung transplantation for cystic fibrosis: results, indications, complications, and controversies. Semin Respir Crit Care Med (2015) 0.76
Administration of Zinc Chelators Improves Survival of Mice Infected with Aspergillus fumigatus both in Monotherapy and in Combination with Caspofungin. Antimicrob Agents Chemother (2016) 0.75
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Coccidioidomycosis. Clin Infect Dis (2005) 3.88
Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother (2002) 3.38
Caspofungin. Clin Infect Dis (2003) 3.03
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell (2010) 2.54
Coccidioidomycosis. Infect Dis Clin North Am (2003) 2.13
Phylogenetic analysis reveals a cryptic species Blastomyces gilchristii, sp. nov. within the human pathogenic fungus Blastomyces dermatitidis. PLoS One (2013) 1.79
Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother (2006) 1.76
Antifungal drug resistance. Clin Infect Dis (2003) 1.65
Saccharomyces as a vaccine against systemic aspergillosis: 'the friend of man' a friend again? J Med Microbiol (2011) 1.52
Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol (2009) 1.49
Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis (2003) 1.44
Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology (2002) 1.43
Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother (2003) 1.36
Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother (2005) 1.23
Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother (2002) 1.22
Development of a murine model of cerebral aspergillosis. J Infect Dis (2002) 1.19
Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol (2011) 1.08
Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med Mycol (2006) 1.06
Candida parapsilosis fungemia in neonates: genotyping results suggest healthcare workers hands as source, and review of published studies. Mycopathologia (2007) 1.05
New polymorphic microsatellite markers able to distinguish among Candida parapsilosis sensu stricto isolates. J Clin Microbiol (2010) 1.02
Animal models: an important tool in mycology. Med Mycol (2007) 1.01
Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis. Infect Immun (2004) 1.00
Levels of matrix metalloproteinase-9 within cerebrospinal fluid in a rabbit model of coccidioidal meningitis and vasculitis. J Infect Dis (2002) 1.00
Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother (2008) 0.98
Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis. Antimicrob Agents Chemother (2004) 0.98
Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn Microbiol Infect Dis (2008) 0.98
Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity. Antimicrob Agents Chemother (2012) 0.97
Metallic taste from electrical and chemical stimulation. Chem Senses (2005) 0.97
Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis (2007) 0.96
Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother (2006) 0.96
Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother (2004) 0.94
Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs. Antimicrob Agents Chemother (2006) 0.93
Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis. Med Mycol (2011) 0.92
Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens. Antimicrob Agents Chemother (2012) 0.92
Regulation by granulocyte-macrophage colony-stimulating factor and/or steroids given in vivo of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia. J Infect Dis (2003) 0.91
Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. Antimicrob Agents Chemother (2005) 0.90
Inhibitor kappaB and nuclear factor kappaB in granulocyte-macrophage colony-stimulating factor antagonism of dexamethasone suppression of the macrophage response to Aspergillus fumigatus conidia. J Infect Dis (2006) 0.90
Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. Vaccine (2009) 0.89
Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport (2003) 0.89
Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection. Vaccine (2011) 0.88
Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis. J Antimicrob Chemother (2007) 0.88
Hormones and the resistance of women to paracoccidioidomycosis. Clin Microbiol Rev (2011) 0.87
Evasion of innate immune responses: evidence for mannose binding lectin inhibition of tumor necrosis factor alpha production by macrophages in response to Blastomyces dermatitidis. Infect Immun (2007) 0.87
Efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection. Antimicrob Agents Chemother (2003) 0.87
Demonstration of a novel technique to quantitatively assess inflammatory mediators and cells in rat knee joints. J Inflamm (Lond) (2007) 0.86
Genetic susceptibility of mice to Candida albicans vaginitis correlates with host estrogen sensitivity. Infect Immun (2004) 0.86
Collectins and fungal pathogens: roles of surfactant proteins and mannose binding lectin in host resistance. Med Mycol (2010) 0.86
A murine model of coccidioidal meningitis. J Infect Dis (2003) 0.86
Who let the dogs out? Infection control did: utility of dogs in health care settings and infection control aspects. Am J Infect Control (2006) 0.86
Vaccination with mannan protects mice against systemic aspergillosis. Med Mycol (2012) 0.86
Call for a California coccidioidomycosis consortium to face the top ten challenges posed by a recalcitrant regional disease. Mycopathologia (2014) 0.85
Effect of lung surfactant collectins on bronchoalveolar macrophage interaction with Blastomyces dermatitidis: inhibition of tumor necrosis factor alpha production by surfactant protein D. Infect Immun (2006) 0.85
Genomic DNA microarray comparison of gene expression patterns in Paracoccidioides brasiliensis mycelia and yeasts in vitro. Microbiology (2009) 0.84
Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. Microbes Infect (2004) 0.84
Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J Antimicrob Chemother (2005) 0.83
Real-time PCR and quantitative culture for monitoring of experimental Aspergillus fumigatus intracranial infection in neutropenic mice. J Med Microbiol (2011) 0.83
Aspergillus vertebral osteomyelitis in immunocompetent hosts: role of triazole antifungal therapy. Clin Infect Dis (2011) 0.83
Saccharomyces as a vaccine against systemic candidiasis. Immunol Invest (2012) 0.82
Experimental systemic infection with Cryptococcus neoformans var. grubii and Cryptococcus gattii in normal and immunodeficient mice. Med Mycol (2006) 0.82
Influence of 17β-estradiol on gene expression of Paracoccidioides during mycelia-to-yeast transition. PLoS One (2011) 0.82
Global population structure of Aspergillus terreus inferred by ISSR typing reveals geographical subclustering. BMC Microbiol (2011) 0.82
Experimental animal models of coccidioidomycosis. Ann N Y Acad Sci (2007) 0.81
Resistance of MBL gene-knockout mice to experimental systemic aspergillosis. Immunol Lett (2010) 0.81
Inflammatory marker profiles in an avian experimental model of aspergillosis. Med Mycol (2013) 0.81
Genotypic differences of Candida albicans and C. dubliniensis isolates related to ethnic/racial differences within the same geographic area. Mycopathologia (2004) 0.81
Molecular epidemiology of the global and temporal diversity of Candida parapsilosis. Scand J Infect Dis (2008) 0.81
Microsatellite multilocus genotyping clarifies the relationship of Candida parapsilosis strains involved in a neonatal intensive care unit outbreak. Diagn Microbiol Infect Dis (2011) 0.81
Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions. Curr Opin Infect Dis (2006) 0.80
Draft genome sequence of the human pathogen Halomonas stevensii S18214T. J Bacteriol (2012) 0.80
Coccidioidal meningitis. Clin Infect Dis (2006) 0.80
Advances against aspergillosis. Clin Infect Dis (2003) 0.80
Protein targets for broad-spectrum mycosis vaccines: quantitative proteomic analysis of Aspergillus and Coccidioides and comparisons with other fungal pathogens. Ann N Y Acad Sci (2012) 0.80
Comparative efficacies of lipid-complexed amphotericin B and liposomal amphotericin B against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother (2009) 0.79
Experimental evidence that granulocyte transfusions are efficacious in treatment of neutropenic hosts with pulmonary aspergillosis. Antimicrob Agents Chemother (2013) 0.78
Mycologic catastrophe. Antimicrob Agents Chemother (2013) 0.78
Efficacy of voriconazole in Japanese quail (Coturnix japonica) experimentally infected with Aspergillus fumigatus. Med Mycol (2010) 0.78
DNA binding compounds targeting fungal pathogens: an emerging concept in the discovery of novel antifungal agents. Curr Opin Investig Drugs (2002) 0.78
Pharmacokinetics of voriconazole in adult mallard ducks (Anas platyrhynchos). Med Mycol (2010) 0.78
A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever. J Med Microbiol (2009) 0.78
Aspergillus fumigatus invasion increases with progressive airway ischemia. PLoS One (2013) 0.78
Susceptibility to pulmonary blastomycosis in young compared to adult mice: immune deficiencies in young mice. Med Mycol (2006) 0.78
Protection of peritoneal macrophages by granulocyte/macrophage colony-stimulating factor (GM-CSF) against dexamethasone suppression of killing of Aspergillus, and the effect of human GM-CSF. Microbes Infect (2002) 0.77
Microbiology and epidemiology of Halomonas species. Future Microbiol (2013) 0.77
Molecular epidemiology of Saccharomyces cerevisiae in an immunocompromised host unit. Diagn Microbiol Infect Dis (2010) 0.77
Killed Saccharomyces cerevisiae protects against lethal challenge of Cryptococcus grubii. Mycopathologia (2014) 0.77
Efficacy of recombinant human mannose binding lectin alone and in combination with itraconazole against murine Candida albicans vaginitis. Immunol Invest (2011) 0.77
Immunomodulatory effects of antifungal agents on the response of human monocytic cells to Aspergillus fumigatus conidia. Med Mycol (2010) 0.76
A new method for the treatment of chronic fungal meningitis: continuous infusion into the cerebrospinal fluid for coccidioidal meningitis. Am J Med Sci (2009) 0.76
Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis. Antimicrob Agents Chemother (2006) 0.76
Immunological basis for susceptibility and resistance to pulmonary blastomycosis in mouse strains. Cytokine (2005) 0.76
Molecular epidemiology of Candida. J Clin Microbiol (2002) 0.75